IP Library Granted Patent US 7,517,518
Granted Patent B2
US 7,517,518 · App. 10/496,173 · Granted Apr 14, 2009

Method for diagnosis of sepsis with determination of ca 125

Assignee: B.R.A.H.M.S Aktiengesellschaft
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,517,518
App. No.
10/496,173
Granted
Apr 14, 2009
Kind
B2
Abstract

The invention relates to a method for the early differential diagnosis and detection, prognosis and determination of the degree of severity of a case of sepsis and systemic infections similar to sepsis and also for the determination of the course of infection during therapy. The above is achieved, whereby the amount of CA 125 in a biological fluid from a patient is determined, preferably with determination of at least one further parameter suitable for diagnosis of sepsis, for a patient who has sepsis or is suspected of having sepsis and, from the determined amounts of CA 125 conclusions are drawn as to the presence, expected course, the degree and/or the success of measures taken for the therapy of sepsis.

Claims (5)

1. A method of confirming a clinical diagnosis of sepsis in a patient suspected of having sepsis, the method comprising determining the concentration of cancer antigen 125 (CA 125) and procalcitonin in a blood or serum sample derived from said patient; and comparing said concentrations to the corresponding concentrations in a control sample, wherein elevated concentrations of CA 125 and procalcitonin in said patient sample with reference to said control sample is indicative of sepsis.

2. The method according to claim 1 , wherein the concentration of CA 125 and procalcitonin is determined by an immunodiagnostic assay.

3. The method according to claim 1 , wherein said determining step relating to the concentration of CA 125 and procalcitonin is performed simultaneously.

4. The method according to claim 1 , wherein said determining step is performed by means of a chip technology measuring apparatus or an immunochromatographic measuring apparatus.

5. The method according to claim 4 , wherein said measuring apparatus provides a measured result that is evaluated with the aid of a computer program.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2013
From: BERGMANN, ANDREAS, DR
To: SPHINGOTEC GMBH
Reel/Frame 031030/0960 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2013
From: B.R.A.H.M.S. GMBH
To: BERGMANN, ANDREAS, DR.
Reel/Frame 031013/0914 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2011
From: B.R.A.H.M.S AKTIENGESELLSCHAFT
To: B.R.A.H.M.S GMBH
Reel/Frame 025697/0943 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2004
From: BERGMANN, ANDREAS
To: B.R.A.H.M.S. AKTIENGESELLSCHAFT
Reel/Frame 015958/0714 →
Priority Claims (1)
EP 01128848 · Dec 4, 2001 · regional
Continuity (1)
Related Publication 20050074811A1 · Apr 7, 2005